中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

101 records (took 0.04 seconds)

    THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES
    64.
    发明申请
    THERAPEUTIC USE OF SPECIFIC LIGAND IN MSRV ASSOCIATED DISEASES 审中-公开
    特异性配偶在MSRV相关疾病中的治疗应用

    公开(公告)号：US20140220026A1

    公开(公告)日：2014-08-07

    申请号：US14221963

    申请日：2014-03-21

    Applicant: GENEURO SA

    Inventor： Corinne BERNARD ,  Alois Bernhardt LANG ,  Herve PERRON ,  Jean-Baptiste BERTRAND

    IPC: C07K16/10

    CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

    Abstract: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

    Abstract translation: 配体包括SEQ ID No.1，SEQ ID No.2，SEQ ID No.3，SEQ ID No.4，SEQ ID No.5和SEQ ID No.6所示的每个互补决定区（CDR） 或在CDR1（SEQ ID No.1）中为0〜3，CDR2（SEQ ID No.2）为0〜2，0〜2的任意序列，在所述序列内具有任意数量的取代氨基酸的序列， 在CDR3（SEQ ID No.3）中，在CDR4（SEQ ID No.4）中为0至1，CDR5（SEQ ID No.5）为0至4，CDR6为0至2（SEQ ID No.6 ）或在所述序列SEQ ID No.1至SEQ ID No.6内具有等同化学功能和性质的其它氨基酸取代的氨基酸。

    Simian T-cell lymphotropic virus
    65.
    发明授权
    Simian T-cell lymphotropic virus 有权
    猿猴T细胞淋巴细胞病毒

    公开(公告)号：US08663968B2

    公开(公告)日：2014-03-04

    申请号：US12600995

    申请日：2008-05-20

    Applicant: William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  David M. Sintasath

    Inventor： William M. Switzer ,  Walid Heneine ,  Thomas M. Folks ,  Nathan D. Wolfe ,  Donald S. Burke ,  David M. Sintasath

    IPC: C12N15/09 ,  C12N7/00 ,  A61K39/00

    CPC classification number: C07K14/005 ,  C07K16/1036 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/14021 ,  C12N2740/14022 ,  C12N2740/14043 ,  G01N33/56983

    Abstract: Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which included isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.

    Abstract translation: 公开了3型亚型T型细胞淋巴细胞病毒（STLV-3亚型D），编码STLV-3亚型D多肽的分离的核酸分子，例如STLV-3亚型D包膜，蛋白酶，聚合酶，tax，rex， 和衣壳多肽，由这种核酸编码的分离的多肽。 还公开了用于检测STLV-3亚型D的方法，例如通过检测样品中的STLV-3亚型D核酸或多肽。 因此，公开了用于检测STLV-3亚型D核酸或多肽的探针，引物和抗体。 还公开了包含编码STLV-3亚型D多肽的分离的核酸分子或由这种核酸分子编码的分离的多肽的治疗组合物。

    Gammaretrovirus associated with cancer
    68.
    发明申请
    Gammaretrovirus associated with cancer 失效
    与癌症相关的瘤胃病毒

    公开(公告)号：US20100166797A1

    公开(公告)日：2010-07-01

    申请号：US11903756

    申请日：2007-09-24

    Applicant: Robert H. Silverman ,  Eric A. Klein ,  Graham Casey ,  Joseph DeRisi ,  Don Ganem

    Inventor： Robert H. Silverman ,  Eric A. Klein ,  Graham Casey ,  Joseph DeRisi ,  Don Ganem

    IPC: A61K39/21 ,  C12N7/00 ,  C07K2/00 ,  C12N15/74 ,  C12N5/10 ,  C07K16/00 ,  C12Q1/70 ,  A61K39/00 ,  A61P35/00 ,  A61P31/12 ,  A61P37/04

    CPC classification number: C12N7/00 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1036 ,  C12N9/22 ,  C12N2740/13021 ,  C12N2740/13022 ,  C12Q1/6886 ,  C12Q1/70 ,  C12Q1/701 ,  C12Q2600/136

    Abstract: The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.

    Abstract translation: 本发明提供了编码病毒的分离的核酸序列; 包含病毒的氨基酸序列的分离的多肽; 包含病毒核酸序列的载体; 包含载体的细胞; 对病毒具有结合特异性的抗体及其抗原结合片段; 检测或筛选病毒的方法（例如，在个体中）; 识别抑制病毒的药剂的方法; 诱导对病毒的免疫应答的方法; 治疗与个体（例如癌症如前列腺癌）中XMRV存在相关的疾病的方法; 检测无症状癌症的方法（例如前列腺癌）; 识别患有癌症风险的个体（例如前列腺癌）的方法; 和用于检测病毒的工具包。

    Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
    69.
    发明申请
    Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG 审中-公开
    衍生自HERV-K18的超抗原（SAg）ENV蛋白的肽及其在获得SAG抑制性抗体和针对SAG的疫苗接种中的用途

    公开(公告)号：US20030162263A1

    公开(公告)日：2003-08-28

    申请号：US10236091

    申请日：2002-09-06

    Inventor： Marc Dupuis

    IPC: C12P021/06 ,  C12P019/34 ,  C07K014/00 ,  C07K007/00 ,  A61K039/12 ,  C07K002/00 ,  C07K004/00 ,  C07K005/00 ,  C07K016/00 ,  C07K017/00 ,  A61K038/00

    CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6081 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10034

    Abstract: The present invention relates to peptides derived from the superantigen (SAg) ENV protein of the human endogenous retrovirus HERV-K18, and to the use of the peptides in obtaining antibodies which inhibit the superantigen activity of HERV-K18 ENV. The invention also relates to vaccine compositions for treating and preventing disorders associated with the ENV gene product of HERV-K18, for example autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM). A preferred peptide consists of a portion of an N- or C-terminal segment of the HERV-K18.1 ENV protein, as illustrated in FIG. 1A, said N-terminal segment extending from amino acids 22 to 62 of HERV-K18.1 ENV, and said C-terminal segment extending from amino acids 110 to 153 of HERV-K18.1 ENV, wherein the peptide has a length of 6 to 40 amino acids and is capable of giving rise to antibodies which inhibit superantigen activity associated with HERV-K18 envelope proteins.

    Abstract translation: 本发明涉及源自人内源性逆转录病毒HERV-K18的超抗原（SAg）ENV蛋白的肽，以及该肽在获得抑制HERV-K18 ENV的超抗原活性的抗体中的用途。 本发明还涉及用于治疗和预防与HERV-K18的ENV基因产物相关的病症的疫苗组合物，例如自身免疫性疾病如胰岛素依赖性糖尿病（IDDM）。 优选的肽由HERV-K18.1 ENV蛋白的N-或C-末端片段的一部分组成，如图中的交叉参考对象。 1，从HERV-K18.1 ENV的氨基酸22至62延伸的所述N-末端片段和从HERV-K18.1 ENV的氨基酸110至153延伸的所述C-末端片段， 其中所述肽具有6至40个氨基酸的长度，并且能够产生抑制与HERV-K18包膜蛋白相关的超抗原活性的抗体。

    Monoclonal antibodies for detection of friend murine leukemia virus
    70.
    发明授权
    Monoclonal antibodies for detection of friend murine leukemia virus 失效
    用于检测朋友鼠白血病病毒的单克隆抗体

    公开(公告)号：US06403300B1

    公开(公告)日：2002-06-11

    申请号：US07694302

    申请日：1991-05-02

    Applicant: Michael N. Robertson ,  Bruce Chesebro ,  Masaaki Miyazawa ,  William J. Britt

    Inventor： Michael N. Robertson ,  Bruce Chesebro ,  Masaaki Miyazawa ,  William J. Britt

    IPC: C12Q170

    CPC classification number: G01N33/56983 ,  C07K16/1036 ,  G01N2333/15

    Abstract: The present invention relates to Friend murine leukemia virus (F-MuLV) specific monoclonal antibodies, or binding fragments thereof, specific for an antigenic determinant of a gp85 envelope precursor protein characteristic of a methanol-fixed F-MuLV infected cell. The invention also relates to hybridomas resulting from the fusion of myeloma cells and spleen cells, which hybridomas produce a Friend murine leukemia virus (F-MuLV) specific monoclonal antibody specific for an antigenic determinant of a gp85 envelope precursor protein characteristic of a methanol-fixed F-MuLV infected cell. The invention further relates to kits containing the above-described monoclonal antibodies.

    Abstract translation: 本发明涉及对甲醇固定的F-MuLV感染细胞特征的gp85包膜前体蛋白的抗原决定簇特异性的Friend鼠白血病病毒（F-MuLV）特异性单克隆抗体或其结合片段。 本发明还涉及由骨髓瘤细胞和脾细胞融合产生的杂交瘤，其杂交瘤产生特异于甲醇固定的gp85包膜前体蛋白的抗原决定簇特异性的Friend鼠白血病病毒（F-MuLV）特异性单克隆抗体 F-MuLV感染细胞。 本发明还涉及含有上述单克隆抗体的试剂盒。

Patent Agency Ranking